Bioxytran ( OTCQB:BIXT ) said Crystal research noted that its oral drug for COVID-19 met the goals of safety and efficacy in a phase 2 trial.
Crystal reported that the Bioxytran announced data from a phase 2 trial of 34 patients with mild-to-moderate COVID-19.
During the seven days of treatment, an orally administered Galectin antagonist in the form of a chewable tablet was administered 8 times per day on an hourly basis.
The company said the trial met its goal with a 100% response rate by day 7 versus 6% in placebo, which was statistically significant.
The company added that its analysis also showed an 88% response rate by day 3, which was statistically significant.
Earlier in December, Bioxytran said that it had set up an Indian subsidiary called Pharmalectin India to launch commercial product sales of ProLectin-M if the company receives approval from the Central Drugs Standard Control Organization (CDSCO). Bioxytran had noted that the Indian manufacturing plant is an FDA approved facility.
Prior to this, Bioxytran said it received an investigational new drug (IND) authorization letter from CDSCO to optimize dosage in patients with COVID-19 in an optimization trial which will guide a 408 patient phase 3 study.
For further details see:
Bioxytran chewable drug for COVID-19 meets phase 2 trial's goals